MAGL-IN-22

MAGL-IN-22 (Compound 40) is a reversible, competitive, selective and BBB-penetrable MAGL inhibitor with an IC50 of 0.34 μM for hMAGL. MAGL-IN-22 has significant antioxidant and anti-inflammatory activity, and activates the Nrf2 pathway and significantly inhibits NFκB-mediated inflammation, without inducing cytotoxic effects. MAGL-IN-22 can be used for neurodegenerative diseases, chronic pain and cancers research[1].

Product Specifications

CAS Number

[2720674-71-3]

UNSPSC

12352005

Target

Keap1-Nrf2; MAGL; NF-κB

Related Pathways

Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Smiles

O=C(CCCC1=CC=CC=C1)NC2=C(C=CC(C3=CC(F)=C(C=C3)O)=C2)O

Molecular Formula

C22H20FNO3

Molecular Weight

365.40

References & Citations

[1]Bononi G, et al. Discovery of reversible monoacylglycerol lipase (MAGL) inhibitors based on ortho-hydroxyanilide scaffold. Bioorg Chem. 2025 Aug;163:108698.